Objective  To explore the effectiveness of clinical pharmacists participating in anti-infection treatment for severe infection patients in the intensive care unit.

Methods  A retrospective collection of severe infection patients admitted to the ICU of the Fourth People's Hospital of Jinan from January to June 2023 was conducted through the hospital information system. Among them, some patients with clinical pharmacists participating in anti-infection treatment throughout the process were in the intervention group, and other patients who did not participate in treatment were in the control group. Both groups of patients received routine treatment according to clinical diagnosis. We compared the cure rate, incidence of adverse reactions, cost of antibiotics, proportion of antibiotic costs, pathogen testing rate, duration of antibiotic treatment, and average length of hospital stay between two groups of patients, and conducted statistical analysis.

Results  A total of 147 patients were included, with 66 in the intervention group and 81 in the control group. The cure rate of patients in the intervention group was 65.15%, significantly higher than 46.91% in the control group (P<0.05); The incidence of adverse reactions (7.58%) was significantly lower than that of the control group (19.75%) (P<0.05). The usage rates of quinolone drugs and tigecycline were significantly reduced in the intervention group; The intervention group had significantly better indicators such as antibiotic costs, proportion of antibiotic costs, and patient pathogen testing rate than the control group (P<0.05). There were no significant difference in the duration of antimicrobial treatment and average length of hospital stay between the two groups (P>0.05).

Conclusion  The full participation of clinical pharmacists in the anti-infection treatment of ICU severe infection patients can help improve their clinical cure rate and medication safety, and reduce their medical burden.

1.邹晶晶, 汤巧美, 吕珂, 等. 急诊科重症患者医院感染病原菌及其影响因素[J]. 中华医院感染学杂志, 2024, 34(8): 1260-1263. [Zou JJ, Tang QM, Lyu K, et al. Pathogenic bacteria distribution and influencing factors for nosocomial infection in severe patients in the emergency department[J]. Chinese Journal of Nosocomiology, 2024, 34(8): 1260-1263.] DOI: 10.11816/cn.ni.2024-230055.

2.Fierens J, Depuydt PO, De Waele JJ. A practical approach to clinical antibiotic stewardship in the ICU patient with severe infection[J]. Semin Respir Crit Care Med, 2019, 40(4): 435-446. DOI: 10.1055/s-0039-1693995.

3.廖玉芳, 李飞, 闫建华, 等. 临床药师在ICU感染性休克患者抗感染治疗中的作用[J]. 中国药房, 2020, 31(11): 1382-1386. [Liao YF, Li F, Yan JH, et al. Role of clinical pharmacists in anti-infective therapy for patients with septic shock in ICU[J]. China Pharmacy, 2020, 31(11): 1382-1386.] DOI: 10.6039/j.issn.1001-0408.2020.11.17.

4.王平, 李红, 苏丹霞. 2017-2021年某三甲医院综合ICU医院感染患者的感染病原菌菌种及耐药性分析[J]. 山东医药, 2022, 62(27): 30-35. [Wang P, Li H, Su DX. Infectious agent strains and drug resistance in patients with nosocomial infection in comprehensive ICU of a class a tertiary hospital from 2017 to 2021[J]. Shangdong Medical Journal, 2022, 62(27): 30-35.] DOI: 10.3969/j.issn.1002-266X.2022.27.007.

5.中国医师协会急诊医师分会. 中国急诊感染性休克临床实践指南[J]. 中国急救医学, 2016, 36(3): 193-206. DOI: 10.3969/j.issn.1002-1949.2016.03.001.

6.Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. DOI: 10.1001/jama.2016.0287.

7.《抗菌药物临床试验技术指导原则》写作组. 抗菌药物临床试验技术指导原则[J]. 中国临床药理学杂志, 2014, 30(9): 844-856. DOI: 10.13699/j.cnki.1001-6821. 2014.09.030.

8.国家卫生健康委员会. 药品不良反应报告和监测管理办法[EB/OL]. (2011-05-14) [2024-06-30]. http://www.nhc.gov.cn/fzs/s3576/201105/ac4ab24c135a43379f2af1694457f65e. shtml.

9.胡付品, 郭燕, 朱德妹, 等. 2021年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2022, 22(5): 521-530. [Hu FP, Guo Y, Zhu DM, et al. CHINET surveillance of antimicrobial resistance among the bacterial isolates in 2021[J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(5): 521-530.] DOI: 10.16718/j.1009-7708.2022. 05.001.

10.国家卫生健康委员会. 抗菌药物临床应用管理办法 [EB/OL]. (2012-04-24) [2024-06-30]. http://www.nhc.gov.cn/wjw/c100022/202201/8fcae32c3f1f467eb795ee816e2387d6.shtml.

11.Zhou CC, Huang F, Zhang JM, et al. Population pharmacokinetics of tigecycline: asystematic review[J]. Drug Des Devel Ther, 2022, 16: 1885-1896. DOI: 10.2147/DDDT.S365512.

12.Zha L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis[J]. Adv Ther, 2020, 37(3): 1049-1064. DOI: 10.1007/s12325-020-01235-y.

13.Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review[J]. Eur J Clin Microbiol Infect Dis, 2022, 41(7): 1003-1022. DOI: 10.1007/s10096- 020-04121-1.

14.Brown NM, Goodman AL, Horner C, et al. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK[J]. JAC Antimicrob Resist, 2021, 3(1): dlaa114. DOI: 10.1093/jacamr/dlaa114.

15.Dehbanipour R, Ghalavand Z. Acinetobacter baumannii: pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline[J]. J Clin Pharm Ther, 2022, 47(11): 1875-1884. DOI: 10.1111/jcpt.13787.

16.Ni W, Han Y, Zhao J, et al. Tigecycline treatment experience against multidrug-resistant acinetobacter baumannii infections: a systematic review and meta-analysis[J]. Int J Antimicrob Agents, 2016, 47(2): 107-116. DOI: 10.1016/j.ijantimicag.2015.11.011.

17.周煊平, 任俊丽, 鲁汝淇, 等. 替加环素致不良反应的国内外文献分析[J]. 中国医院用药评价与分析, 2023, 23(2): 241-244. [Zhou XP, Ren JL, Lu RQ, et al. Domestic and foreign literature of adverse drug reactions induced by tigecycline[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2023, 23(2): 241-244.] DOI: 10.14009/j.issn.1672-2124.2023.02.024.

18.蔡泽政, 唐颖, 张梅花, 等. 2021-2023某三甲医院替加环素临床应用评价分析[J]. 中国药物滥用防治杂志, 2024, 30(4): 648-654. [Cai ZZ, Tang Y, Zhang MH, et al. Evaluation and analysis of clinical application of tigecycline in a tertiary hospital from 2021 to 2023[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2024, 30(4): 648-654.] DOI: 10.15900/j.cnki.zylf1995.2024.04.016.

19.韩龙, 闫美兴, 刘畅. 临床药师参与72例重症监护室感染患者药学会诊分析及典型病例[J]. 中国药学杂志, 2024, 59(7): 640-645. [Han L, Yan MX, Liu C. Analysis of pharmaceutical consultation of 72 patients with infection in ICU and introduction of typical cases with clinical pharmacist's participation[J]. Chinese Pharmaceutical Journal, 2024, 59(7): 640-645.] DOI: 10.11669/cpj.2024. 07.010.

20.王海涛, 张抗怀, 谢姣, 等. 临床药师对重症监护室抗菌药物相关药物相互作用的研究及药学服务[J]. 中国药师, 2023, 26(10): 125-131. [Wang HT, Zhang KH, Xie  J, et al. Research and pharmaceutical services by clinical pharmacists on antibiotic-related drug interaction in ICU[J]. China Pharmacist, 2023, 26(10): 125-131.] DOI: 10.12173/j.issn.1008-049X.202205707.

21.许川, 赖晓全, 徐敏, 等. 多学科协作管理模式提高住院患者抗菌药物治疗前病原学送检率的应用效果 [J]. 中华医院感染学杂志, 2023, 33(21): 3321-3326. [Xu C, Lai XQ, Xu M, et al. Effect of multi-disciplinary cooperation mode on raising etiological submission rate of hospitalized patients before antibiotic therapy[J]. Chinese Journal of Nosocomiology, 2023, 33(21): 3321-3326.] DOI: 10.11816/cn.ni.2023-238012.

22.Guilhaumou R, Chevrier C, Setti JL, et al. β-Lactam pharmacokinetic/pharmacodynamic target attainment in intensive care unit patients: a prospective, observational, cohort study[J]. Antibiotics (Basel), 2023, 12(8): 1289. DOI: 10.3390/antibiotics12081289.

23.中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志, 2018, 41(6): 409-446. DOI: 10.3760/cma.j.issn.1001-0939. 2018.06.004.

24.Helset E, Cheng V, Sporsem H, et al. Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in ICU patients: a prospective observational study[J]. Acta Anaesthesiol Scand, 2024, 68(4): 502-511.] DOI: 10.1111/aas.14376.

25.杨雪容, 何元媛, 杨柔, 等. 药学门诊实践及其对提高医院医疗质量的促进作用[J]. 医药导报, 2023, 42(5): 639-644. [Yang XR, He YY, Yang R, et al. Practice of pharmacist-managed clinic and its promoting effect on medical quality in hospitals[J]. Herald of Medicine, 2023, 42(5): 639-644.] DOI: 10.3870/j.issn.1004-0781. 2023.05.004.

26.刘高峰, 陈孝, 张毕奎, 等. 中国医院药学学科的建设与发展[J]. 中国药学杂志, 2023, 58(22): 1993-2015. [Liu GF, Chen X, Zhang BK, et al. Construction and development of hospital pharmacy discipline in China[J]. Chinese Pharmaceutical Journal, 2023, 58(22): 1993-2015.] DOI: 10.11669/cpj.2023.22.001.